nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—NR1I2—Paclitaxel—ovarian cancer	0.423	0.514	CbGbCtD
Rifaximin—NR1I2—Docetaxel—ovarian cancer	0.306	0.372	CbGbCtD
Rifaximin—CYP3A4—Topotecan—ovarian cancer	0.0335	0.0407	CbGbCtD
Rifaximin—CYP3A4—Vinorelbine—ovarian cancer	0.0236	0.0287	CbGbCtD
Rifaximin—CYP3A4—Paclitaxel—ovarian cancer	0.0166	0.0201	CbGbCtD
Rifaximin—CYP3A4—Docetaxel—ovarian cancer	0.012	0.0146	CbGbCtD
Rifaximin—CYP3A4—Doxorubicin—ovarian cancer	0.00894	0.0109	CbGbCtD
Rifaximin—NR1I2—Nuclear Receptors—NR5A1—ovarian cancer	0.00042	0.165	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—NR5A1—ovarian cancer	0.000332	0.13	CbGpPWpGaD
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—ABCB1—ovarian cancer	0.000278	0.109	CbGpPWpGaD
Rifaximin—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000215	0.00123	CcSEcCtD
Rifaximin—Mental disorder—Docetaxel—ovarian cancer	0.000214	0.00123	CcSEcCtD
Rifaximin—Arthralgia—Paclitaxel—ovarian cancer	0.000214	0.00123	CcSEcCtD
Rifaximin—Chest pain—Paclitaxel—ovarian cancer	0.000214	0.00123	CcSEcCtD
Rifaximin—Myalgia—Paclitaxel—ovarian cancer	0.000214	0.00123	CcSEcCtD
Rifaximin—Nasopharyngitis—Epirubicin—ovarian cancer	0.000213	0.00123	CcSEcCtD
Rifaximin—Malnutrition—Docetaxel—ovarian cancer	0.000213	0.00122	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000212	0.00122	CcSEcCtD
Rifaximin—Nausea—Topotecan—ovarian cancer	0.000211	0.00122	CcSEcCtD
Rifaximin—Discomfort—Paclitaxel—ovarian cancer	0.000211	0.00121	CcSEcCtD
Rifaximin—Dry mouth—Paclitaxel—ovarian cancer	0.000209	0.0012	CcSEcCtD
Rifaximin—NR1I2—Nuclear Receptors—PGR—ovarian cancer	0.000209	0.082	CbGpPWpGaD
Rifaximin—Diarrhoea—Vinorelbine—ovarian cancer	0.000208	0.0012	CcSEcCtD
Rifaximin—Abdominal distension—Epirubicin—ovarian cancer	0.000207	0.00119	CcSEcCtD
Rifaximin—Nausea—Melphalan—ovarian cancer	0.000207	0.00119	CcSEcCtD
Rifaximin—Confusional state—Paclitaxel—ovarian cancer	0.000207	0.00119	CcSEcCtD
Rifaximin—Dysphagia—Epirubicin—ovarian cancer	0.000206	0.00118	CcSEcCtD
Rifaximin—Back pain—Docetaxel—ovarian cancer	0.000206	0.00118	CcSEcCtD
Rifaximin—Dehydration—Doxorubicin—ovarian cancer	0.000205	0.00118	CcSEcCtD
Rifaximin—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000205	0.00118	CcSEcCtD
Rifaximin—Muscle spasms—Docetaxel—ovarian cancer	0.000205	0.00118	CcSEcCtD
Rifaximin—Infection—Paclitaxel—ovarian cancer	0.000204	0.00117	CcSEcCtD
Rifaximin—Shock—Paclitaxel—ovarian cancer	0.000202	0.00116	CcSEcCtD
Rifaximin—Dizziness—Vinorelbine—ovarian cancer	0.000201	0.00116	CcSEcCtD
Rifaximin—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000201	0.00116	CcSEcCtD
Rifaximin—Nervous system disorder—Paclitaxel—ovarian cancer	0.000201	0.00116	CcSEcCtD
Rifaximin—Skin disorder—Paclitaxel—ovarian cancer	0.000199	0.00114	CcSEcCtD
Rifaximin—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000199	0.00114	CcSEcCtD
Rifaximin—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000198	0.00114	CcSEcCtD
Rifaximin—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000197	0.00113	CcSEcCtD
Rifaximin—Anaemia—Docetaxel—ovarian cancer	0.000197	0.00113	CcSEcCtD
Rifaximin—Anorexia—Paclitaxel—ovarian cancer	0.000195	0.00112	CcSEcCtD
Rifaximin—Vomiting—Vinorelbine—ovarian cancer	0.000194	0.00111	CcSEcCtD
Rifaximin—Dysuria—Epirubicin—ovarian cancer	0.000193	0.00111	CcSEcCtD
Rifaximin—Neutropenia—Epirubicin—ovarian cancer	0.000193	0.00111	CcSEcCtD
Rifaximin—Rash—Vinorelbine—ovarian cancer	0.000192	0.0011	CcSEcCtD
Rifaximin—Dermatitis—Vinorelbine—ovarian cancer	0.000192	0.0011	CcSEcCtD
Rifaximin—Abdominal distension—Doxorubicin—ovarian cancer	0.000192	0.0011	CcSEcCtD
Rifaximin—Hypotension—Paclitaxel—ovarian cancer	0.000191	0.0011	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000191	0.0011	CcSEcCtD
Rifaximin—Headache—Vinorelbine—ovarian cancer	0.000191	0.0011	CcSEcCtD
Rifaximin—Syncope—Docetaxel—ovarian cancer	0.000191	0.0011	CcSEcCtD
Rifaximin—Dysphagia—Doxorubicin—ovarian cancer	0.000191	0.0011	CcSEcCtD
Rifaximin—Pollakiuria—Epirubicin—ovarian cancer	0.00019	0.00109	CcSEcCtD
Rifaximin—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000188	0.00108	CcSEcCtD
Rifaximin—Weight increased—Epirubicin—ovarian cancer	0.000187	0.00108	CcSEcCtD
Rifaximin—Loss of consciousness—Docetaxel—ovarian cancer	0.000187	0.00108	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000187	0.00107	CcSEcCtD
Rifaximin—Weight decreased—Epirubicin—ovarian cancer	0.000186	0.00107	CcSEcCtD
Rifaximin—Hyperglycaemia—Epirubicin—ovarian cancer	0.000186	0.00107	CcSEcCtD
Rifaximin—Cough—Docetaxel—ovarian cancer	0.000186	0.00107	CcSEcCtD
Rifaximin—Insomnia—Paclitaxel—ovarian cancer	0.000185	0.00107	CcSEcCtD
Rifaximin—Pneumonia—Epirubicin—ovarian cancer	0.000185	0.00106	CcSEcCtD
Rifaximin—Infestation NOS—Epirubicin—ovarian cancer	0.000184	0.00106	CcSEcCtD
Rifaximin—Infestation—Epirubicin—ovarian cancer	0.000184	0.00106	CcSEcCtD
Rifaximin—Dyspnoea—Paclitaxel—ovarian cancer	0.000183	0.00105	CcSEcCtD
Rifaximin—Arthralgia—Docetaxel—ovarian cancer	0.000181	0.00104	CcSEcCtD
Rifaximin—Chest pain—Docetaxel—ovarian cancer	0.000181	0.00104	CcSEcCtD
Rifaximin—Myalgia—Docetaxel—ovarian cancer	0.000181	0.00104	CcSEcCtD
Rifaximin—Nausea—Vinorelbine—ovarian cancer	0.000181	0.00104	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00018	0.00103	CcSEcCtD
Rifaximin—Dysuria—Doxorubicin—ovarian cancer	0.000178	0.00103	CcSEcCtD
Rifaximin—Neutropenia—Doxorubicin—ovarian cancer	0.000178	0.00103	CcSEcCtD
Rifaximin—Decreased appetite—Paclitaxel—ovarian cancer	0.000178	0.00102	CcSEcCtD
Rifaximin—Dry mouth—Docetaxel—ovarian cancer	0.000177	0.00102	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000177	0.00102	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000177	0.00102	CcSEcCtD
Rifaximin—Fatigue—Paclitaxel—ovarian cancer	0.000177	0.00102	CcSEcCtD
Rifaximin—Pollakiuria—Doxorubicin—ovarian cancer	0.000176	0.00101	CcSEcCtD
Rifaximin—Pain—Paclitaxel—ovarian cancer	0.000175	0.00101	CcSEcCtD
Rifaximin—Constipation—Paclitaxel—ovarian cancer	0.000175	0.00101	CcSEcCtD
Rifaximin—Haematuria—Epirubicin—ovarian cancer	0.000175	0.00101	CcSEcCtD
Rifaximin—Confusional state—Docetaxel—ovarian cancer	0.000175	0.00101	CcSEcCtD
Rifaximin—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000174	0.001	CcSEcCtD
Rifaximin—Anaphylactic shock—Docetaxel—ovarian cancer	0.000174	0.000999	CcSEcCtD
Rifaximin—Weight increased—Doxorubicin—ovarian cancer	0.000173	0.000998	CcSEcCtD
Rifaximin—Epistaxis—Epirubicin—ovarian cancer	0.000173	0.000996	CcSEcCtD
Rifaximin—Infection—Docetaxel—ovarian cancer	0.000172	0.000992	CcSEcCtD
Rifaximin—Weight decreased—Doxorubicin—ovarian cancer	0.000172	0.000992	CcSEcCtD
Rifaximin—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000172	0.000989	CcSEcCtD
Rifaximin—Pneumonia—Doxorubicin—ovarian cancer	0.000171	0.000983	CcSEcCtD
Rifaximin—Shock—Docetaxel—ovarian cancer	0.000171	0.000983	CcSEcCtD
Rifaximin—Nervous system disorder—Docetaxel—ovarian cancer	0.00017	0.00098	CcSEcCtD
Rifaximin—Infestation NOS—Doxorubicin—ovarian cancer	0.00017	0.000977	CcSEcCtD
Rifaximin—Infestation—Doxorubicin—ovarian cancer	0.00017	0.000977	CcSEcCtD
Rifaximin—Feeling abnormal—Paclitaxel—ovarian cancer	0.000169	0.000971	CcSEcCtD
Rifaximin—Skin disorder—Docetaxel—ovarian cancer	0.000169	0.00097	CcSEcCtD
Rifaximin—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000168	0.000964	CcSEcCtD
Rifaximin—Haemoglobin—Epirubicin—ovarian cancer	0.000166	0.000953	CcSEcCtD
Rifaximin—Anorexia—Docetaxel—ovarian cancer	0.000166	0.000952	CcSEcCtD
Rifaximin—Rhinitis—Epirubicin—ovarian cancer	0.000165	0.000951	CcSEcCtD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—PGR—ovarian cancer	0.000165	0.0648	CbGpPWpGaD
Rifaximin—Haemorrhage—Epirubicin—ovarian cancer	0.000165	0.000948	CcSEcCtD
Rifaximin—Hypoaesthesia—Epirubicin—ovarian cancer	0.000164	0.000943	CcSEcCtD
Rifaximin—Pharyngitis—Epirubicin—ovarian cancer	0.000164	0.000941	CcSEcCtD
Rifaximin—Urinary tract disorder—Epirubicin—ovarian cancer	0.000163	0.000936	CcSEcCtD
Rifaximin—Urticaria—Paclitaxel—ovarian cancer	0.000163	0.000936	CcSEcCtD
Rifaximin—Oedema peripheral—Epirubicin—ovarian cancer	0.000162	0.000934	CcSEcCtD
Rifaximin—Hypotension—Docetaxel—ovarian cancer	0.000162	0.000933	CcSEcCtD
Rifaximin—Haematuria—Doxorubicin—ovarian cancer	0.000162	0.000932	CcSEcCtD
Rifaximin—Abdominal pain—Paclitaxel—ovarian cancer	0.000162	0.000932	CcSEcCtD
Rifaximin—Body temperature increased—Paclitaxel—ovarian cancer	0.000162	0.000932	CcSEcCtD
Rifaximin—Urethral disorder—Epirubicin—ovarian cancer	0.000162	0.00093	CcSEcCtD
Rifaximin—Epistaxis—Doxorubicin—ovarian cancer	0.00016	0.000922	CcSEcCtD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.00016	0.0628	CbGpPWpGaD
Rifaximin—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000158	0.00091	CcSEcCtD
Rifaximin—Insomnia—Docetaxel—ovarian cancer	0.000157	0.000903	CcSEcCtD
Rifaximin—Dyspnoea—Docetaxel—ovarian cancer	0.000155	0.00089	CcSEcCtD
Rifaximin—Tinnitus—Epirubicin—ovarian cancer	0.000154	0.000884	CcSEcCtD
Rifaximin—Haemoglobin—Doxorubicin—ovarian cancer	0.000153	0.000882	CcSEcCtD
Rifaximin—Flushing—Epirubicin—ovarian cancer	0.000153	0.00088	CcSEcCtD
Rifaximin—Rhinitis—Doxorubicin—ovarian cancer	0.000153	0.00088	CcSEcCtD
Rifaximin—Haemorrhage—Doxorubicin—ovarian cancer	0.000153	0.000877	CcSEcCtD
Rifaximin—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000152	0.000873	CcSEcCtD
Rifaximin—Pharyngitis—Doxorubicin—ovarian cancer	0.000151	0.000871	CcSEcCtD
Rifaximin—Decreased appetite—Docetaxel—ovarian cancer	0.000151	0.000868	CcSEcCtD
Rifaximin—Hypersensitivity—Paclitaxel—ovarian cancer	0.000151	0.000868	CcSEcCtD
Rifaximin—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000151	0.000866	CcSEcCtD
Rifaximin—Oedema peripheral—Doxorubicin—ovarian cancer	0.00015	0.000864	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00015	0.000862	CcSEcCtD
Rifaximin—Fatigue—Docetaxel—ovarian cancer	0.00015	0.000861	CcSEcCtD
Rifaximin—Angiopathy—Epirubicin—ovarian cancer	0.00015	0.00086	CcSEcCtD
Rifaximin—Urethral disorder—Doxorubicin—ovarian cancer	0.00015	0.00086	CcSEcCtD
Rifaximin—Mediastinal disorder—Epirubicin—ovarian cancer	0.000149	0.000855	CcSEcCtD
Rifaximin—Pain—Docetaxel—ovarian cancer	0.000148	0.000854	CcSEcCtD
Rifaximin—Constipation—Docetaxel—ovarian cancer	0.000148	0.000854	CcSEcCtD
Rifaximin—Asthenia—Paclitaxel—ovarian cancer	0.000147	0.000845	CcSEcCtD
Rifaximin—Pruritus—Paclitaxel—ovarian cancer	0.000145	0.000834	CcSEcCtD
Rifaximin—Mental disorder—Epirubicin—ovarian cancer	0.000144	0.000831	CcSEcCtD
Rifaximin—Malnutrition—Epirubicin—ovarian cancer	0.000143	0.000825	CcSEcCtD
Rifaximin—Feeling abnormal—Docetaxel—ovarian cancer	0.000143	0.000823	CcSEcCtD
Rifaximin—Tinnitus—Doxorubicin—ovarian cancer	0.000142	0.000818	CcSEcCtD
Rifaximin—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000142	0.000817	CcSEcCtD
Rifaximin—Flushing—Doxorubicin—ovarian cancer	0.000142	0.000814	CcSEcCtD
Rifaximin—Flatulence—Epirubicin—ovarian cancer	0.000141	0.000813	CcSEcCtD
Rifaximin—Diarrhoea—Paclitaxel—ovarian cancer	0.00014	0.000806	CcSEcCtD
Rifaximin—Back pain—Epirubicin—ovarian cancer	0.000139	0.000798	CcSEcCtD
Rifaximin—Angiopathy—Doxorubicin—ovarian cancer	0.000138	0.000796	CcSEcCtD
Rifaximin—Muscle spasms—Epirubicin—ovarian cancer	0.000138	0.000794	CcSEcCtD
Rifaximin—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000137	0.000791	CcSEcCtD
Rifaximin—Body temperature increased—Docetaxel—ovarian cancer	0.000137	0.00079	CcSEcCtD
Rifaximin—Abdominal pain—Docetaxel—ovarian cancer	0.000137	0.00079	CcSEcCtD
Rifaximin—Dizziness—Paclitaxel—ovarian cancer	0.000135	0.000779	CcSEcCtD
Rifaximin—Mental disorder—Doxorubicin—ovarian cancer	0.000134	0.000769	CcSEcCtD
Rifaximin—Ill-defined disorder—Epirubicin—ovarian cancer	0.000133	0.000766	CcSEcCtD
Rifaximin—Malnutrition—Doxorubicin—ovarian cancer	0.000133	0.000764	CcSEcCtD
Rifaximin—Anaemia—Epirubicin—ovarian cancer	0.000133	0.000763	CcSEcCtD
Rifaximin—Flatulence—Doxorubicin—ovarian cancer	0.000131	0.000753	CcSEcCtD
Rifaximin—Vomiting—Paclitaxel—ovarian cancer	0.00013	0.000749	CcSEcCtD
Rifaximin—Malaise—Epirubicin—ovarian cancer	0.000129	0.000744	CcSEcCtD
Rifaximin—Rash—Paclitaxel—ovarian cancer	0.000129	0.000743	CcSEcCtD
Rifaximin—Dermatitis—Paclitaxel—ovarian cancer	0.000129	0.000742	CcSEcCtD
Rifaximin—Vertigo—Epirubicin—ovarian cancer	0.000129	0.000742	CcSEcCtD
Rifaximin—Syncope—Epirubicin—ovarian cancer	0.000129	0.00074	CcSEcCtD
Rifaximin—Back pain—Doxorubicin—ovarian cancer	0.000128	0.000739	CcSEcCtD
Rifaximin—Headache—Paclitaxel—ovarian cancer	0.000128	0.000738	CcSEcCtD
Rifaximin—Hypersensitivity—Docetaxel—ovarian cancer	0.000128	0.000736	CcSEcCtD
Rifaximin—Muscle spasms—Doxorubicin—ovarian cancer	0.000128	0.000734	CcSEcCtD
Rifaximin—Loss of consciousness—Epirubicin—ovarian cancer	0.000126	0.000726	CcSEcCtD
Rifaximin—Cough—Epirubicin—ovarian cancer	0.000125	0.00072	CcSEcCtD
Rifaximin—Asthenia—Docetaxel—ovarian cancer	0.000125	0.000717	CcSEcCtD
Rifaximin—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000123	0.000709	CcSEcCtD
Rifaximin—Pruritus—Docetaxel—ovarian cancer	0.000123	0.000707	CcSEcCtD
Rifaximin—Anaemia—Doxorubicin—ovarian cancer	0.000123	0.000706	CcSEcCtD
Rifaximin—Arthralgia—Epirubicin—ovarian cancer	0.000122	0.000703	CcSEcCtD
Rifaximin—Chest pain—Epirubicin—ovarian cancer	0.000122	0.000703	CcSEcCtD
Rifaximin—Myalgia—Epirubicin—ovarian cancer	0.000122	0.000703	CcSEcCtD
Rifaximin—Nausea—Paclitaxel—ovarian cancer	0.000122	0.0007	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000121	0.000698	CcSEcCtD
Rifaximin—Discomfort—Epirubicin—ovarian cancer	0.000121	0.000694	CcSEcCtD
Rifaximin—Malaise—Doxorubicin—ovarian cancer	0.00012	0.000689	CcSEcCtD
Rifaximin—Dry mouth—Epirubicin—ovarian cancer	0.000119	0.000687	CcSEcCtD
Rifaximin—Vertigo—Doxorubicin—ovarian cancer	0.000119	0.000686	CcSEcCtD
Rifaximin—Syncope—Doxorubicin—ovarian cancer	0.000119	0.000685	CcSEcCtD
Rifaximin—Diarrhoea—Docetaxel—ovarian cancer	0.000119	0.000683	CcSEcCtD
Rifaximin—Confusional state—Epirubicin—ovarian cancer	0.000118	0.000679	CcSEcCtD
Rifaximin—Anaphylactic shock—Epirubicin—ovarian cancer	0.000117	0.000674	CcSEcCtD
Rifaximin—Loss of consciousness—Doxorubicin—ovarian cancer	0.000117	0.000671	CcSEcCtD
Rifaximin—Infection—Epirubicin—ovarian cancer	0.000116	0.000669	CcSEcCtD
Rifaximin—Cough—Doxorubicin—ovarian cancer	0.000116	0.000666	CcSEcCtD
Rifaximin—Shock—Epirubicin—ovarian cancer	0.000115	0.000663	CcSEcCtD
Rifaximin—Nervous system disorder—Epirubicin—ovarian cancer	0.000115	0.000661	CcSEcCtD
Rifaximin—Dizziness—Docetaxel—ovarian cancer	0.000115	0.00066	CcSEcCtD
Rifaximin—Skin disorder—Epirubicin—ovarian cancer	0.000114	0.000654	CcSEcCtD
Rifaximin—Hyperhidrosis—Epirubicin—ovarian cancer	0.000113	0.000651	CcSEcCtD
Rifaximin—Myalgia—Doxorubicin—ovarian cancer	0.000113	0.00065	CcSEcCtD
Rifaximin—Arthralgia—Doxorubicin—ovarian cancer	0.000113	0.00065	CcSEcCtD
Rifaximin—Chest pain—Doxorubicin—ovarian cancer	0.000113	0.00065	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000112	0.000646	CcSEcCtD
Rifaximin—Discomfort—Doxorubicin—ovarian cancer	0.000112	0.000642	CcSEcCtD
Rifaximin—Anorexia—Epirubicin—ovarian cancer	0.000112	0.000642	CcSEcCtD
Rifaximin—NR1I2—Nuclear Receptors—ESR1—ovarian cancer	0.000112	0.0438	CbGpPWpGaD
Rifaximin—Dry mouth—Doxorubicin—ovarian cancer	0.000111	0.000636	CcSEcCtD
Rifaximin—Vomiting—Docetaxel—ovarian cancer	0.00011	0.000635	CcSEcCtD
Rifaximin—Rash—Docetaxel—ovarian cancer	0.000109	0.00063	CcSEcCtD
Rifaximin—Hypotension—Epirubicin—ovarian cancer	0.000109	0.00063	CcSEcCtD
Rifaximin—Dermatitis—Docetaxel—ovarian cancer	0.000109	0.000629	CcSEcCtD
Rifaximin—Confusional state—Doxorubicin—ovarian cancer	0.000109	0.000629	CcSEcCtD
Rifaximin—Headache—Docetaxel—ovarian cancer	0.000109	0.000626	CcSEcCtD
Rifaximin—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000108	0.000623	CcSEcCtD
Rifaximin—Infection—Doxorubicin—ovarian cancer	0.000108	0.000619	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000107	0.000614	CcSEcCtD
Rifaximin—Shock—Doxorubicin—ovarian cancer	0.000107	0.000613	CcSEcCtD
Rifaximin—Nervous system disorder—Doxorubicin—ovarian cancer	0.000106	0.000611	CcSEcCtD
Rifaximin—Insomnia—Epirubicin—ovarian cancer	0.000106	0.000609	CcSEcCtD
Rifaximin—Skin disorder—Doxorubicin—ovarian cancer	0.000105	0.000605	CcSEcCtD
Rifaximin—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000105	0.000603	CcSEcCtD
Rifaximin—Dyspnoea—Epirubicin—ovarian cancer	0.000104	0.000601	CcSEcCtD
Rifaximin—Anorexia—Doxorubicin—ovarian cancer	0.000103	0.000594	CcSEcCtD
Rifaximin—Nausea—Docetaxel—ovarian cancer	0.000103	0.000593	CcSEcCtD
Rifaximin—Decreased appetite—Epirubicin—ovarian cancer	0.000102	0.000586	CcSEcCtD
Rifaximin—Hypotension—Doxorubicin—ovarian cancer	0.000101	0.000582	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000101	0.000582	CcSEcCtD
Rifaximin—Fatigue—Epirubicin—ovarian cancer	0.000101	0.000581	CcSEcCtD
Rifaximin—Pain—Epirubicin—ovarian cancer	0.0001	0.000576	CcSEcCtD
Rifaximin—Constipation—Epirubicin—ovarian cancer	0.0001	0.000576	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	9.87e-05	0.000568	CcSEcCtD
Rifaximin—Insomnia—Doxorubicin—ovarian cancer	9.8e-05	0.000564	CcSEcCtD
Rifaximin—Dyspnoea—Doxorubicin—ovarian cancer	9.66e-05	0.000556	CcSEcCtD
Rifaximin—Feeling abnormal—Epirubicin—ovarian cancer	9.65e-05	0.000555	CcSEcCtD
Rifaximin—Gastrointestinal pain—Epirubicin—ovarian cancer	9.58e-05	0.000551	CcSEcCtD
Rifaximin—Decreased appetite—Doxorubicin—ovarian cancer	9.42e-05	0.000542	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Doxorubicin—ovarian cancer	9.35e-05	0.000538	CcSEcCtD
Rifaximin—Fatigue—Doxorubicin—ovarian cancer	9.34e-05	0.000537	CcSEcCtD
Rifaximin—Urticaria—Epirubicin—ovarian cancer	9.3e-05	0.000535	CcSEcCtD
Rifaximin—Pain—Doxorubicin—ovarian cancer	9.27e-05	0.000533	CcSEcCtD
Rifaximin—Constipation—Doxorubicin—ovarian cancer	9.27e-05	0.000533	CcSEcCtD
Rifaximin—Body temperature increased—Epirubicin—ovarian cancer	9.26e-05	0.000533	CcSEcCtD
Rifaximin—Abdominal pain—Epirubicin—ovarian cancer	9.26e-05	0.000533	CcSEcCtD
Rifaximin—Feeling abnormal—Doxorubicin—ovarian cancer	8.93e-05	0.000514	CcSEcCtD
Rifaximin—Gastrointestinal pain—Doxorubicin—ovarian cancer	8.86e-05	0.00051	CcSEcCtD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—ESR1—ovarian cancer	8.82e-05	0.0346	CbGpPWpGaD
Rifaximin—Hypersensitivity—Epirubicin—ovarian cancer	8.63e-05	0.000496	CcSEcCtD
Rifaximin—Urticaria—Doxorubicin—ovarian cancer	8.61e-05	0.000495	CcSEcCtD
Rifaximin—Body temperature increased—Doxorubicin—ovarian cancer	8.57e-05	0.000493	CcSEcCtD
Rifaximin—Abdominal pain—Doxorubicin—ovarian cancer	8.57e-05	0.000493	CcSEcCtD
Rifaximin—Asthenia—Epirubicin—ovarian cancer	8.4e-05	0.000483	CcSEcCtD
Rifaximin—Pruritus—Epirubicin—ovarian cancer	8.29e-05	0.000477	CcSEcCtD
Rifaximin—Diarrhoea—Epirubicin—ovarian cancer	8.01e-05	0.000461	CcSEcCtD
Rifaximin—Hypersensitivity—Doxorubicin—ovarian cancer	7.98e-05	0.000459	CcSEcCtD
Rifaximin—Asthenia—Doxorubicin—ovarian cancer	7.77e-05	0.000447	CcSEcCtD
Rifaximin—Dizziness—Epirubicin—ovarian cancer	7.74e-05	0.000445	CcSEcCtD
Rifaximin—Pruritus—Doxorubicin—ovarian cancer	7.67e-05	0.000441	CcSEcCtD
Rifaximin—Vomiting—Epirubicin—ovarian cancer	7.45e-05	0.000428	CcSEcCtD
Rifaximin—Diarrhoea—Doxorubicin—ovarian cancer	7.41e-05	0.000427	CcSEcCtD
Rifaximin—Rash—Epirubicin—ovarian cancer	7.38e-05	0.000425	CcSEcCtD
Rifaximin—Dermatitis—Epirubicin—ovarian cancer	7.38e-05	0.000424	CcSEcCtD
Rifaximin—Headache—Epirubicin—ovarian cancer	7.34e-05	0.000422	CcSEcCtD
Rifaximin—Dizziness—Doxorubicin—ovarian cancer	7.17e-05	0.000412	CcSEcCtD
Rifaximin—Nausea—Epirubicin—ovarian cancer	6.96e-05	0.0004	CcSEcCtD
Rifaximin—Vomiting—Doxorubicin—ovarian cancer	6.89e-05	0.000396	CcSEcCtD
Rifaximin—Rash—Doxorubicin—ovarian cancer	6.83e-05	0.000393	CcSEcCtD
Rifaximin—Dermatitis—Doxorubicin—ovarian cancer	6.83e-05	0.000393	CcSEcCtD
Rifaximin—Headache—Doxorubicin—ovarian cancer	6.79e-05	0.000391	CcSEcCtD
Rifaximin—CYP3A4—Liver X Receptor Pathway—FASN—ovarian cancer	6.57e-05	0.0258	CbGpPWpGaD
Rifaximin—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—ovarian cancer	6.51e-05	0.0255	CbGpPWpGaD
Rifaximin—Nausea—Doxorubicin—ovarian cancer	6.44e-05	0.00037	CcSEcCtD
Rifaximin—CYP3A4—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	5.89e-05	0.0231	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—NR5A1—ovarian cancer	5.73e-05	0.0225	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—WDR77—ovarian cancer	3.87e-05	0.0152	CbGpPWpGaD
Rifaximin—CYP3A4—Estrogen metabolism—CYP1B1—ovarian cancer	3.74e-05	0.0147	CbGpPWpGaD
Rifaximin—CYP3A4—Tamoxifen metabolism—CYP1B1—ovarian cancer	3.3e-05	0.013	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—YAP1—ovarian cancer	3.27e-05	0.0128	CbGpPWpGaD
Rifaximin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—ovarian cancer	3.22e-05	0.0126	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—TTF1—ovarian cancer	3.04e-05	0.0119	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—PGR—ovarian cancer	2.85e-05	0.0112	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—NR5A1—ovarian cancer	2.76e-05	0.0108	CbGpPWpGaD
Rifaximin—CYP3A4—Irinotecan Pathway—APC—ovarian cancer	2.71e-05	0.0106	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—PARP1—ovarian cancer	2.65e-05	0.0104	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	1.94e-05	0.00762	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	1.85e-05	0.00726	CbGpPWpGaD
Rifaximin—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	1.76e-05	0.00692	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—YAP1—ovarian cancer	1.57e-05	0.00617	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—ESR1—ovarian cancer	1.52e-05	0.00598	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	1.43e-05	0.0056	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	1.41e-05	0.00552	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PGR—ovarian cancer	1.37e-05	0.00539	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PARP1—ovarian cancer	1.28e-05	0.00501	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	1.16e-05	0.00454	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PPP2R1A—ovarian cancer	1.04e-05	0.00406	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—MYC—ovarian cancer	7.92e-06	0.00311	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—ESR1—ovarian cancer	7.33e-06	0.00288	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	6.14e-06	0.00241	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	6.06e-06	0.00238	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MAPK3—ovarian cancer	3.92e-06	0.00154	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MYC—ovarian cancer	3.81e-06	0.0015	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NME2—ovarian cancer	3.74e-06	0.00147	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—AKT1—ovarian cancer	2.65e-06	0.00104	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYTB—ovarian cancer	2.41e-06	0.000947	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPP1CC—ovarian cancer	2.11e-06	0.000828	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—BRIP1—ovarian cancer	2.11e-06	0.000828	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—YAP1—ovarian cancer	1.41e-06	0.000555	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—FASN—ovarian cancer	1.15e-06	0.000453	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.13e-06	0.000445	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.1e-06	0.00043	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.05e-06	0.000412	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	9.31e-07	0.000366	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCB1—ovarian cancer	8.65e-07	0.000339	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—TYMS—ovarian cancer	8.49e-07	0.000333	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CAV1—ovarian cancer	6.84e-07	0.000269	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CG—ovarian cancer	6.23e-07	0.000245	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CD—ovarian cancer	5.48e-07	0.000215	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CB—ovarian cancer	4.78e-07	0.000187	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PTEN—ovarian cancer	4.13e-07	0.000162	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.91e-07	0.000114	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AKT1—ovarian cancer	2.38e-07	9.34e-05	CbGpPWpGaD
